

## Patent Claims

1. Method of treatment of an individual suffering from a liver disease, or at risk of contracting a liver disease unless treated, said method comprising the step of administering to the individual a composition comprising a pharmaceutically effective amount of IGF-1, or a variant thereof.

2. Method of claim 1, wherein said individual is a human being.

3. Method of claim 1, wherein said liver disease is acute liver disease.

4. Method of claim 3, wherein said liver disease is liver failure.

5. Method of claim 3, wherein said liver disease occurs in combination with malnutrition.

6. Method of claim 3, wherein said liver disease occurs in combination with insulin resistance.

7. Method of claim 3, wherein said liver disease occurs in combination with IGF-1 deficiency.

8. Method of claim 1, wherein said liver disease is chronic liver disease.

9. Method of claim 8, wherein said liver disease is cirrhosis of the liver.

10. Method of claim 8, wherein said liver disease is fibrosis of the liver.

11. Method of claim 8, wherein said liver disease is chronic hepatitis.

12. Method of claim 8, wherein said liver disease occurs in combination with a metabolic disorder.
13. Method of claim 8, wherein said liver disease occurs in combination with malnutrition.
14. Method of claim 8, wherein said liver disease occurs in combination with insulin resistance.
15. Method of claim 8, wherein said liver disease occurs in combination with diabetes mellitus.
16. Method of claim 8, wherein said liver disease occurs in combination with IGF-1 deficiency.
17. Method of claim 1, wherein said pharmaceutically effective amount of IGF-1 is less than 200 microgram and more than 25 microgram per day per kilo gram of treated individual.
18. Method of claim 1, wherein said pharmaceutically effective amount of IGF-1 is about 100 microgram per day per kilogram of treated individual.
19. Method of claim 1, wherein the IGF-1 is recombinant IGF-1, or a variant thereof, produced by recombinant DNA technology.
20. Method of claim 1, wherein said composition further comprises at least one IGF-1 binding protein (IGFBP) selected from the group consisting of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6, and variants thereof.
21. Method of claim 2, wherein said composition further comprises at least one IGF-1 binding protein (IGFBP) selected from the group consisting of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6, and variants thereof.
22. Method of claim 9, wherein said composition further

---